Addiction risk is mostly about impulse control genes, not drug-specific biology

Why does addiction run in families? The intuitive answer - that some people's bodies respond more strongly to specific drugs - turns out to be only a small part of the story. According to the largest genomic dissection of substance use disorders to date, the majority of inherited addiction risk has nothing to do with how the body handles alcohol, nicotine, cannabis, or opioids. It comes from how the brain is wired for impulse control.

Two pathways, very different scales

The study, published in Nature Mental Health and led by Holly Poore at Rutgers Robert Wood Johnson Medical School, analyzed genetic data from genome-wide association studies encompassing more than 2.2 million individuals. The researchers examined four substance use disorders - alcohol, tobacco, cannabis, and opioids - alongside related behavioral traits including ADHD, risk-taking, and substance use initiation.

What emerged were two distinct genetic pathways to addiction risk, operating at very different scales.

The first pathway is broad. It involves genes that influence behavioral disinhibition - the umbrella term for difficulty regulating impulses, poor self-control, heightened reward-seeking, and a tendency toward risk-taking. These genes affect how the brain processes rewards, weighs future consequences against immediate gratification, and applies the brakes to impulsive behavior. This pathway cuts across all four substances and connects to other externalizing conditions like ADHD and conduct problems.

The second pathway is narrow and substance-specific. These are genes tied to particular biological interactions with individual drugs: alcohol metabolism enzymes, nicotinic acetylcholine receptors involved in tobacco response, and similar drug-specific mechanisms. These genes matter, but they account for a smaller share of overall genetic risk than the broad behavioral pathway.

"Most of the genetic predisposition to substance use disorders isn't about how bodies respond to drugs; it's about how brains are wired," said Danielle Dick, director of the Rutgers Addiction Research Center and senior author. "Specifically, risk is mostly related to genes that broadly impact how our brains process rewards and regulate behavior."

Seeing more by looking at everything together

The methodological insight is as important as the finding itself. Traditional gene-finding studies have examined one substance use disorder at a time - one genome-wide association study for alcohol, another for tobacco, another for opioids. But decades of twin and family studies have shown that these disorders share substantial genetic overlap. By studying them separately, researchers were essentially looking at fragments of a single picture.

Poore's team modeled all four substance use disorders simultaneously, alongside the externalizing traits they share genetic roots with. This approach dramatically increased statistical power to detect genetic associations without sacrificing the ability to identify substance-specific signals. The shared architecture, once modeled explicitly, revealed hundreds of genetic variants associated with the broad externalizing liability that individual-disorder studies had missed.

"Traditionally, gene-finding efforts have focused on one disorder at a time," Poore said. "But substance use disorders almost never occur in isolation, and decades of twin and family studies have shown that they share a lot of their genetic roots with each other and with other externalizing conditions. By modeling that shared genetic architecture directly, we were able to discover more about both the broad and specific biological pathways that contribute to addiction."

From gene lists to biological systems

The genes linked to the broad externalizing pathway were not random. They clustered in biological systems involved in brain signaling, reward processing, and neural plasticity - the brain's capacity to strengthen or weaken connections based on experience. These are systems that shape how a person learns from consequences, how intensely they experience pleasure, and how effectively they can override a desire for immediate reward when longer-term costs are apparent.

The substance-specific genes, by contrast, mapped onto more targeted biological mechanisms. Genes involved in alcohol metabolism showed up specifically for alcohol use disorder. Nicotinic acetylcholine receptor genes appeared specifically for tobacco. These pathways modulate how the body processes a particular substance and how the brain responds to its pharmacological effects.

The layered architecture suggests that addiction vulnerability operates like a two-tier system. The broad pathway sets a general level of risk - a predisposition toward impulsive, reward-seeking behavior that makes problematic substance use more likely regardless of the specific drug. The substance-specific pathways then influence which drug, if any, becomes the primary problem.

Polygenic scores: broad versus specific predictions

The researchers translated their genomic findings into polygenic scores - composite measures that aggregate thousands of genetic variants into a single number reflecting genetic liability. They built two types: broad externalizing scores capturing the shared pathway, and substance-specific scores capturing drug-specific genetic effects.

The broad externalizing polygenic scores were powerful predictors across multiple substance use disorders. A person with a high externalizing score had elevated risk for problems with alcohol, tobacco, cannabis, and opioids alike. The substance-specific scores added precision, identifying who was at particular risk for problems with one drug over another.

"A broader metric can tell us who is generally more vulnerable to addiction and other externalizing problems, while more specific scores can help us understand who is at higher risk for problems with different substances," Dick said. "That doesn't mean genes determine someone's destiny, but they can help us identify who might benefit most from targeted prevention or earlier intervention."

Drug targets hiding in the data

Beyond risk prediction, the researchers conducted network and drug-target analyses that flagged biological systems and existing medications potentially relevant to treatment. Many of the genes identified in the broad externalizing pathway overlapped with those implicated in other psychiatric disorders, suggesting shared biological substrates that might respond to common therapeutic approaches. Some existing medications already target pathways highlighted by the genetic data, raising the possibility of drug repurposing for addiction treatment.

A critical limitation: ancestry and generalizability

The study's most significant constraint is its population. The analyses were limited to individuals of European ancestry, reflecting the current state of large-scale genomic datasets. The genetic variants identified, and the polygenic scores derived from them, may not perform the same way in populations with different genetic backgrounds. Allele frequencies, linkage disequilibrium patterns, and gene-environment interactions all vary across ancestries, and findings from European-descent samples have a documented history of transferring poorly to other groups.

The authors emphasize this limitation explicitly and call for more diverse genomic research. Until the genetic architecture of addiction is mapped across populations, the clinical utility of polygenic risk scores will remain uneven - potentially widening rather than narrowing health disparities if applied prematurely in diverse clinical settings.

Other limitations include the reliance on previously published genome-wide association study data, which varies in quality and diagnostic criteria across contributing cohorts, and the inherent challenge of distinguishing genetic correlation from causal biological mechanism. The statistical associations identified in this study are robust, but translating them into mechanistic understanding and clinical tools requires additional experimental work.

Still, the study's central finding reframes how we think about inherited addiction risk. The genes that matter most are not the ones that determine how your liver metabolizes ethanol or how your nicotine receptors fire. They are the genes that shape whether you can walk past a reward without reaching for it. That distinction has practical implications for prevention, treatment, and the way we understand vulnerability to addiction as a condition rooted in brain architecture rather than substance-specific biology.